EP1981867B1 - Verfahren zur herstellung eines prostaglandinderivats - Google Patents
Verfahren zur herstellung eines prostaglandinderivats Download PDFInfo
- Publication number
- EP1981867B1 EP1981867B1 EP07714040.8A EP07714040A EP1981867B1 EP 1981867 B1 EP1981867 B1 EP 1981867B1 EP 07714040 A EP07714040 A EP 07714040A EP 1981867 B1 EP1981867 B1 EP 1981867B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- group
- solution
- added
- formula
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 238000000034 method Methods 0.000 title claims description 28
- 150000003180 prostaglandins Chemical class 0.000 title claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 229920006395 saturated elastomer Polymers 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 239000002585 base Substances 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000007810 chemical reaction solvent Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 7
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 150000003752 zinc compounds Chemical class 0.000 claims description 7
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims description 6
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000011737 fluorine Substances 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052717 sulfur Chemical group 0.000 claims description 4
- 239000011593 sulfur Chemical group 0.000 claims description 4
- 229910052721 tungsten Inorganic materials 0.000 claims description 4
- 229910052727 yttrium Inorganic materials 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 192
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 108
- 239000000243 solution Substances 0.000 description 87
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 80
- -1 prostaglandin compound Chemical class 0.000 description 50
- 239000000203 mixture Substances 0.000 description 47
- 239000011780 sodium chloride Substances 0.000 description 40
- 239000010410 layer Substances 0.000 description 38
- 238000010898 silica gel chromatography Methods 0.000 description 33
- HMEIVWIWTZUKAC-AVPDHNOJSA-N methyl 7-[(1r,2r,3r,5s)-5-acetyloxy-2-formyl-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound O=C[C@@H]1[C@@H](CCCCCCC(=O)OC)[C@@H](OC(C)=O)C[C@H]1OC1OCCCC1 HMEIVWIWTZUKAC-AVPDHNOJSA-N 0.000 description 32
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 31
- 235000010724 Wisteria floribunda Nutrition 0.000 description 31
- CISDEVRDMKWPCP-UHFFFAOYSA-N 1-dimethoxyphosphoryl-3,3-difluoroheptan-2-one Chemical compound CCCCC(F)(F)C(=O)CP(=O)(OC)OC CISDEVRDMKWPCP-UHFFFAOYSA-N 0.000 description 30
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- MDZMFDYLAZZDMJ-CPXISBAFSA-N methyl 7-[(1r,2r,3r,5s)-5-acetyloxy-2-[(e)-4,4-difluoro-3-oxooct-1-enyl]-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound C1[C@H](OC(C)=O)[C@H](CCCCCCC(=O)OC)[C@@H](/C=C/C(=O)C(F)(F)CCCC)[C@@H]1OC1OCCCC1 MDZMFDYLAZZDMJ-CPXISBAFSA-N 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 19
- 239000011259 mixed solution Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 150000001299 aldehydes Chemical class 0.000 description 14
- 238000001816 cooling Methods 0.000 description 13
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 13
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 13
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000012230 colorless oil Substances 0.000 description 11
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical class [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000012535 impurity Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 150000005215 alkyl ethers Chemical class 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 0 CC1C2(CC2)C(C*)CC1* Chemical compound CC1C2(CC2)C(C*)CC1* 0.000 description 5
- NDHMOBCVFGMXRK-FVCCEPFGSA-N [(3ar,4r,5r,6as)-4-formyl-2-oxo-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-yl] benzoate Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)C=O)C(=O)C1=CC=CC=C1 NDHMOBCVFGMXRK-FVCCEPFGSA-N 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- TXNONRHNSXICDH-QIDNBJOUSA-N (3ar,4s,5r,6as)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]furan-2-ol Chemical compound O([C@H]1[C@@H]([C@H]2CC(O)O[C@H]2C1)CO[Si](C)(C)C(C)(C)C)C1CCCCO1 TXNONRHNSXICDH-QIDNBJOUSA-N 0.000 description 4
- LDRDALYMRZJWSM-XZKIWDHXSA-N (z)-7-[(1r,2s,3r,5s)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-hydroxy-3-(oxan-2-yloxy)cyclopentyl]hept-5-enoic acid Chemical compound C1[C@H](O)[C@H](C\C=C/CCCC(O)=O)[C@@H](CO[Si](C)(C)C(C)(C)C)[C@@H]1OC1OCCCC1 LDRDALYMRZJWSM-XZKIWDHXSA-N 0.000 description 4
- LQZCYXCHWNQBKX-UHFFFAOYSA-N 1-dimethoxyphosphorylheptan-2-one Chemical compound CCCCCC(=O)CP(=O)(OC)OC LQZCYXCHWNQBKX-UHFFFAOYSA-N 0.000 description 4
- BXDMUNJIZCRANF-UHFFFAOYSA-N 3-dimethoxyphosphoryl-1,1-difluoro-1-phenylpropan-2-one Chemical compound COP(=O)(OC)CC(=O)C(F)(F)C1=CC=CC=C1 BXDMUNJIZCRANF-UHFFFAOYSA-N 0.000 description 4
- RIZXCSCPKZIMGB-LURQJERSSA-N 7-[(1r,2r,3r,5s)-2-(4,4-difluoro-3-hydroxyoctyl)-5-hydroxy-3-(oxan-2-yloxy)cyclopentyl]heptanoic acid Chemical compound C1[C@H](O)[C@H](CCCCCCC(O)=O)[C@@H](CCC(O)C(F)(F)CCCC)[C@@H]1OC1OCCCC1 RIZXCSCPKZIMGB-LURQJERSSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- BEVKTMCEJWZGBD-SMPHTAIGSA-N [(3ar,4r,5r,6as)-4-[(e)-4,4-difluoro-3-oxooct-1-enyl]-2-oxo-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-yl] benzoate Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)/C=C/C(=O)C(F)(F)CCCC)C(=O)C1=CC=CC=C1 BEVKTMCEJWZGBD-SMPHTAIGSA-N 0.000 description 4
- MPTRCXJBAZVEAN-NYZYLINDSA-N benzyl 7-[(1r,2r,3r)-2-(4,4-difluoro-3-oxooctyl)-3-(oxan-2-yloxy)-5-oxocyclopentyl]heptanoate Chemical compound C([C@H]1C(=O)C[C@H]([C@@H]1CCC(=O)C(F)(F)CCCC)OC1OCCCC1)CCCCCC(=O)OCC1=CC=CC=C1 MPTRCXJBAZVEAN-NYZYLINDSA-N 0.000 description 4
- DUHLRGISOMMJPA-ZSAXNNEISA-N benzyl 7-[(1r,2r,3r,5s)-2-(4,4-difluoro-3-hydroxyoctyl)-5-hydroxy-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound C([C@H]1[C@@H](O)C[C@H]([C@@H]1CCC(O)C(F)(F)CCCC)OC1OCCCC1)CCCCCC(=O)OCC1=CC=CC=C1 DUHLRGISOMMJPA-ZSAXNNEISA-N 0.000 description 4
- IWLNOXNCSHBARG-SPEYYTFGSA-N benzyl 7-[(2r,4ar,5r,7ar)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxo-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-5-yl]heptanoate Chemical compound C([C@H]1C(=O)C[C@@H]2[C@@H]1CC[C@](O2)(O)C(F)(F)CCCC)CCCCCC(=O)OCC1=CC=CC=C1 IWLNOXNCSHBARG-SPEYYTFGSA-N 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- OADLSKRLIXPQCH-ADCRDVJOSA-N methyl (z)-7-[(1r,2s,3r,5s)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-hydroxy-3-(oxan-2-yloxy)cyclopentyl]hept-5-enoate Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H]1[C@@H](C\C=C/CCCC(=O)OC)[C@@H](O)C[C@H]1OC1OCCCC1 OADLSKRLIXPQCH-ADCRDVJOSA-N 0.000 description 4
- ROVSANRBQGVMPK-QWUWZXSGSA-N methyl 7-[(1r,2r,3r,5s)-5-acetyloxy-2-(4,4-difluoro-3-hydroxyoctyl)-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound C1[C@H](OC(C)=O)[C@H](CCCCCCC(=O)OC)[C@@H](CCC(O)C(F)(F)CCCC)[C@@H]1OC1OCCCC1 ROVSANRBQGVMPK-QWUWZXSGSA-N 0.000 description 4
- IOTUOAJRNQSCCG-GOUKNRKJSA-N methyl 7-[(1r,2r,3r,5s)-5-acetyloxy-2-(4,4-difluoro-3-oxooctyl)-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound C1[C@H](OC(C)=O)[C@H](CCCCCCC(=O)OC)[C@@H](CCC(=O)C(F)(F)CCCC)[C@@H]1OC1OCCCC1 IOTUOAJRNQSCCG-GOUKNRKJSA-N 0.000 description 4
- MZYNJCHMMFIUEP-NDUFDKTRSA-N methyl 7-[(1r,2s,3r,5s)-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-hydroxy-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H]1[C@@H](CCCCCCC(=O)OC)[C@@H](O)C[C@H]1OC1OCCCC1 MZYNJCHMMFIUEP-NDUFDKTRSA-N 0.000 description 4
- LBTFOYZKHZOLPE-AVPDHNOJSA-N methyl 7-[(1r,2s,3r,5s)-5-acetyloxy-2-(hydroxymethyl)-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound OC[C@@H]1[C@@H](CCCCCCC(=O)OC)[C@@H](OC(C)=O)C[C@H]1OC1OCCCC1 LBTFOYZKHZOLPE-AVPDHNOJSA-N 0.000 description 4
- ICRWTSRMZBBGKR-HGXYQMEISA-N methyl 7-[(1r,2s,3r,5s)-5-acetyloxy-2-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound CC(C)(C)[Si](C)(C)OC[C@@H]1[C@@H](CCCCCCC(=O)OC)[C@@H](OC(C)=O)C[C@H]1OC1OCCCC1 ICRWTSRMZBBGKR-HGXYQMEISA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 229910052716 thallium Inorganic materials 0.000 description 4
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- IFRGKGVYYRVIFV-UDSQWYCDSA-N methyl (z)-7-[(1r,2r,3r,5s)-5-acetyloxy-2-formyl-3-(oxan-2-yloxy)cyclopentyl]hept-5-enoate Chemical compound O=C[C@@H]1[C@@H](C\C=C/CCCC(=O)OC)[C@@H](OC(C)=O)C[C@H]1OC1OCCCC1 IFRGKGVYYRVIFV-UDSQWYCDSA-N 0.000 description 3
- JFUVHOKBLSXZBN-YFGIZIHFSA-N methyl 7-[(1r,2r,3r,5s)-5-acetyloxy-2-[(e)-4,4-difluoro-3-oxo-4-phenylbut-1-enyl]-3-(oxan-2-yloxy)cyclopentyl]heptanoate Chemical compound O([C@@H]1C[C@@H]([C@@H]([C@H]1\C=C\C(=O)C(F)(F)C=1C=CC=CC=1)CCCCCCC(=O)OC)OC(C)=O)C1CCCCO1 JFUVHOKBLSXZBN-YFGIZIHFSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- JJMNYDDYIZNLIX-GRDYTRHSSA-N (3ar,4s,5r,6as)-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-(oxan-2-yloxy)-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-one Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)CO[Si](C)(C)C(C)(C)C)C1CCCCO1 JJMNYDDYIZNLIX-GRDYTRHSSA-N 0.000 description 2
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 2
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OCWSJGXEQPXXSZ-QSQWMDCWSA-N [(3ar,4r,5r,6as)-2-oxo-4-[(e)-3-oxooct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-5-yl] benzoate Chemical compound O([C@H]1[C@@H]([C@H]2CC(=O)O[C@H]2C1)/C=C/C(=O)CCCCC)C(=O)C1=CC=CC=C1 OCWSJGXEQPXXSZ-QSQWMDCWSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OEERIBPGRSLGEK-UHFFFAOYSA-N carbon dioxide;methanol Chemical compound OC.O=C=O OEERIBPGRSLGEK-UHFFFAOYSA-N 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- SIAPCJWMELPYOE-UHFFFAOYSA-N lithium hydride Chemical compound [LiH] SIAPCJWMELPYOE-UHFFFAOYSA-N 0.000 description 2
- 229910000103 lithium hydride Inorganic materials 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- LLUAKEOWNJXDCX-WRWCTEDDSA-N methyl (z)-7-[(1r,2r,3r,5s)-5-acetyloxy-2-[(e)-4,4-difluoro-3-oxooct-1-enyl]-3-(oxan-2-yloxy)cyclopentyl]hept-5-enoate Chemical compound C1[C@H](OC(C)=O)[C@H](C\C=C/CCCC(=O)OC)[C@@H](/C=C/C(=O)C(F)(F)CCCC)[C@@H]1OC1OCCCC1 LLUAKEOWNJXDCX-WRWCTEDDSA-N 0.000 description 2
- NYNXRXHRQQTULD-VPTSOSRISA-N methyl 7-[(1r,2r,3r,5s)-5-acetyloxy-3-(oxan-2-yloxy)-2-[(e)-3-oxooct-1-enyl]cyclopentyl]heptanoate Chemical compound C1[C@H](OC(C)=O)[C@H](CCCCCCC(=O)OC)[C@@H](/C=C/C(=O)CCCCC)[C@@H]1OC1OCCCC1 NYNXRXHRQQTULD-VPTSOSRISA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- PNKZBZPLRKCVLI-UHFFFAOYSA-N (2-methylpropan-2-yl)oxybenzene Chemical compound CC(C)(C)OC1=CC=CC=C1 PNKZBZPLRKCVLI-UHFFFAOYSA-N 0.000 description 1
- ULWQQRDHNCMMSB-QQTQMKHKSA-N (2r,4ar,5r,7ar)-2-(1,1-difluoropentyl)-5-heptyl-2-hydroxy-3,4,4a,5,7,7a-hexahydrocyclopenta[b]pyran-6-one Chemical compound C1C[C@](O)(C(F)(F)CCCC)O[C@@H]2CC(=O)[C@H](CCCCCCC)[C@H]21 ULWQQRDHNCMMSB-QQTQMKHKSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical class CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- POEDHWVTLBLWDA-UHFFFAOYSA-N 1-butylindole-2,3-dione Chemical compound C1=CC=C2N(CCCC)C(=O)C(=O)C2=C1 POEDHWVTLBLWDA-UHFFFAOYSA-N 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- UXPPDBVMSPAPCL-UHFFFAOYSA-N 1-prop-1-ynoxyprop-1-yne Chemical compound CC#COC#CC UXPPDBVMSPAPCL-UHFFFAOYSA-N 0.000 description 1
- PLNNBRYFKARCEV-UHFFFAOYSA-N 2-[(2-hydroxyphenyl)methoxymethyl]phenol Chemical compound OC1=CC=CC=C1COCC1=CC=CC=C1O PLNNBRYFKARCEV-UHFFFAOYSA-N 0.000 description 1
- HHBZZTKMMLDNDN-UHFFFAOYSA-N 2-butan-2-yloxybutane Chemical compound CCC(C)OC(C)CC HHBZZTKMMLDNDN-UHFFFAOYSA-N 0.000 description 1
- SGJUFIMCHSLMRJ-UHFFFAOYSA-N 2-hydroperoxypropane Chemical compound CC(C)OO SGJUFIMCHSLMRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- XHWSCQCJAPLELI-UHFFFAOYSA-N 4-(3,4-dimethoxyphenoxy)-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1OC1=CC=C(OC)C(OC)=C1 XHWSCQCJAPLELI-UHFFFAOYSA-N 0.000 description 1
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZKIDXPAMVXFFFT-TXOUICJISA-N CCCCC(C(/C=C/[C@@H](C(COC1OCCCC1)C1)C(CCCCCCC(OC)=O)C1OC(C)=O)=O)(F)F Chemical compound CCCCC(C(/C=C/[C@@H](C(COC1OCCCC1)C1)C(CCCCCCC(OC)=O)C1OC(C)=O)=O)(F)F ZKIDXPAMVXFFFT-TXOUICJISA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229910013724 M(OH)2 Inorganic materials 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- QUXMPZUVBXHUII-UHFFFAOYSA-N [1,1-bis(hydroxymethylamino)ethylamino]methanol Chemical class OCNC(C)(NCO)NCO QUXMPZUVBXHUII-UHFFFAOYSA-N 0.000 description 1
- PVQATPQSBYNMGE-UHFFFAOYSA-N [benzhydryloxy(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)C1=CC=CC=C1 PVQATPQSBYNMGE-UHFFFAOYSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical compound C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- UZBQIPPOMKBLAS-UHFFFAOYSA-N diethylazanide Chemical compound CC[N-]CC UZBQIPPOMKBLAS-UHFFFAOYSA-N 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 150000004656 dimethylamines Chemical class 0.000 description 1
- QKIUAMUSENSFQQ-UHFFFAOYSA-N dimethylazanide Chemical compound C[N-]C QKIUAMUSENSFQQ-UHFFFAOYSA-N 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- LZTCEQQSARXBHE-UHFFFAOYSA-N ethoxycyclopropane Chemical compound CCOC1CC1 LZTCEQQSARXBHE-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000010808 liquid waste Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000003956 methylamines Chemical class 0.000 description 1
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGJJROVFWIXTPA-OALUTQOASA-N prostanoic acid Chemical group CCCCCCCC[C@H]1CCC[C@@H]1CCCCCCC(O)=O WGJJROVFWIXTPA-OALUTQOASA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- UUCCCPNEFXQJEL-UHFFFAOYSA-L strontium dihydroxide Chemical compound [OH-].[OH-].[Sr+2] UUCCCPNEFXQJEL-UHFFFAOYSA-L 0.000 description 1
- 229910001866 strontium hydroxide Inorganic materials 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Substances [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 150000003476 thallium compounds Chemical class 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
Definitions
- the present invention relates to a method for preparing a prostaglandin derivative that is useful for the treatment of a variety of diseases or conditions, or as synthesis intermediates for manufacturing therapeutically active compounds.
- Prostaglandin has a prostanoic acid structure indicated by the formula: and there are many prostaglandins having a variety of therapeutic effects.
- the Corey method is a conventional, well-known and representative method for prostaglandin synthesis.
- the Corey method includes a process wherein an ⁇ , ⁇ -unsaturated ketolactone (III) is obtained from a Corey lactone (I) via a Corey aldehyde (II): wherein Ar is an aromatic group. That is to say, the Corey lactone (I) is oxidized to yield the Corey aldehyde (II), then reacted with an anion (enolate) prepared by the reaction of dimethyl 2-oxoalkyl phosphonate and sodium hydride, to give the ⁇ , ⁇ -unsaturated ketone (III).
- Document EP 0 643 051 discloses a safe technique for improving the yield of an ⁇ , ⁇ -unsaturated ketone through introduction of an ⁇ -chain into an aldehyde without being accompanied by the generation of hydrogen in the process for synthesizing a prostaglandin, in particular, one having at least one halogen atom in the 16- or 17-position.
- the described process comprises conducting the reaction of an aldehyde with a 2-oxoalkylphosphonate in the presence of a base and a zinc compound.
- An object of the present invention is to provide a simple, highly efficient and industrially applicable method for preparing a prostaglandin derivative, especially, those having one or more halogen atoms on the ⁇ chain.
- the present invention provides a method for preparing a prostaglandin derivative of formula (A) :
- the term "unsaturated" in R 1 , R 1 ' and R 3 means to contain at least one or more double-bond and/or triple-bond alone, separately or contiguously, as bonds between carbon atoms of the main chain and/or side chain. According to the general nomenclature, unsaturations between two contiguous positions are indicated by representing the younger position number, and unsaturations between two non-contiguous positions are indicated by representing both position numbers.
- lower to medium aliphatic hydrocarbon means a hydrocarbon having a straight or branched chain having 1 to 14 carbon atoms (for a side chain, 1 to 3 carbon atoms are preferable) and preferably 1 to 10, especially 6 to 10 carbon atoms for R 1 ; 1 to 10, especially, 1 to 6 carbon atoms for R 1 '; and 1 to 10, especially 1 to 8 carbon atoms for R 3 .
- halogen comprises fluorine, chlorine, bromine and iodide.
- lower comprises groups having 1 to 6 carbon atoms, unless specifically stated otherwise.
- lower alkyl comprises straight chain or branched chain saturated hydrocarbon groups having 1 to 6 carbon atoms, for instance, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t -butyl, pentyl and hexyl.
- lower alkoxy means lower alkyl-O-, in which lower alkyl has the same meaning as above.
- lower alkanoyloxy means groups indicated by the formula RCO-O- (herein, RCO- is acyls generated by oxidation of lower alkyls such as those described above, for instance, acetyl).
- cyclo(lower)alkyl comprises cyclic groups generated by cyclization of lower alkyl groups such as those described above, containing three or more carbon atoms, for instance, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- cyclo(lower)alkyloxy means cyclo(lower)alkyl-O-, in which cyclo(lower)alkyl has the same meaning as above.
- aryl comprises aromatic hydrocarbon ring group that may be unsubstituted or non-substituted, preferably monocyclic, for instance, phenyl, tolyl and xylyl can be given as examples.
- Substituents include halogens and halogen-substituted lower alkyl groups (herein, halogens and lower alkyl groups have the aforementioned meanings).
- aryloxy means groups indicated by the formula ArO- (herein, Ar is aryl groups such as those described above).
- heterocyclic group may include mono- to tri-cyclic, preferably monocyclic heterocyclic group which is 5 to 14, preferably 5 to 10 membered ring having optionally substituted carbon atom and 1 to 4, preferably 1 to 3 of 1 or 2 type of hetero atoms selected from nitrogen, oxygen and sulfur.
- heterocyclic group examples include furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, furazanyl, pyranyl, pyridyl, pyridazinyl, pyrimidyl, pyrazinyl, 2-pyrrolinyl, pyrrolidinyl, 2-imidazolinyl, imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, indolyl, benzothienyl, quinolyl, isoquinolyl, purinyl, quinazolinyl, carbazolyl, acridinyl, phenanthridinyl, benzimidazolyl, benzimidazolinyl, benzothiazolyl, phenothia
- heterocyclicoxy group means a group represented by the formula HcO-, wherein Hc is a heterocyclic group as described above.
- the term "functional derivative" for Q includes salts, preferably pharmaceutically acceptable salts, ethers, esters and amides.
- salts with inorganic bases for instance, alkaline metal salts (sodium salt, potassium salt and the like), alkaline earth metal salts (calcium salt, magnesium salt and the like), ammonium salts, salts with organic bases, for instance, amine salts (for instance, methylamine salt, dimethylamine salt, cyclohexyl amine salt, benzylamine salt, piperidine salt, ethylenediamine salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, tris(hydroxymethyl amino)ethane salt, monomethyl-mono ethanolamine salt, procaine salt, caffeine salt and the like), basic amino acid salts (for instance, arginine salt, lysine salt and the like), tetra alkyl ammonium salts, and the like, can be given.
- These salts may be prepared, for instance, from corresponding acids and bases by a conventional reaction or salt exchange.
- alkyl ethers for instance, lower alkyl ethers, such as, methyl ether, ethyl ether, propyl ether, isopropyl ether, butyl ether, isobutyl ether, sec-butyl ether, t -butyl ether, pentyl ether and 1-cyclopropyl ethyl ether, medium or higher alkyl ethers, such as, octyl ether, diethyl hexyl ether, lauryl ether, cetyl ether, unsaturated ethers, such as, oleyl ether and linolenyl ether, lower alkenyl ethers, such as, vinyl ether and allyl ether, lower alkynyl ethers, such as, ethinyl ether and propynyl ether, hydroxy(lower)alkyl ethers, such as, hydroxyethy
- esters aliphatic esters including lower alkyl esters, such as, methyl ester, ethyl ester, propyl ester, isopropyl ester, butyl ester, isobutyl ester, sec-butyl ester, t -butyl ester, pentyl ester and 1-cyclopropyl ethyl ester, lower alkenyl esters, such as, vinyl ester and allyl ester, lower alkynyl esters, such as, ethinyl ester and propynyl ester, hydroxy (lower)alkyl esters, such as, hydroxyethyl ester, lower alkoxy (lower)alkyl esters, such as, methoxy methyl ester and 1-methoxy ethyl ester; and for instance, optionally substituted aryl esters, such as, phenyl ester, tolyl ester, t -butyl phenyl ester,
- the amides of Q means a group represented by the formula -CONR'R", wherein R' and R" are, respectively, a hydrogen, lower alkyl, aryl, alkyl- or aryl-sulfonyl, lower alkenyl and lower alkynyl, and for instance, lower alkyl amides, such as, methyl amide, ethyl amide, dimethylamide and diethylamide, aryl amides, such as, anilide and toluidide, alkyl- or aryl-sulfonyl amides, such as, methyl sulfonyl amide, ethyl sulfonyl amide and tolyl sulfonyl amide, and the like, can be cited.
- Q are -COOH, pharmaceutically acceptable salts, esters and amides thereof.
- Preferred example for B is a single bond
- R 1 are hydrocarbons having 1 to 10 carbon atoms, and especially, hydrocarbons having 6 to 10 carbon atoms.
- at least one carbon atom in the aliphatic hydrocarbon may be optionally substituted by an oxygen, a nitrogen or a sulfur.
- R 1 examples include, for example, the following groups:
- Preferred R 3 is an unsubstituted hydrocarbon having 1 to 10, and preferably 1 to 8 carbon atoms.
- X 1 and X 2 cases where at least one is a halogen are preferred, in particular, cases where both are halogen, especially fluorine, are preferred.
- Examples of A 1 and A 2 may comprise the entirety of those groups forming protecting groups for hydroxy groups, and a protecting group for a hydroxy group means a functional group that is introduced to inactivate the hydroxy group against a specific reaction in order to avoid an undesirable chemical reaction, and as long as it conforms to this purpose, is not limited in particular.
- a method for preparing a prostaglandin derivative especially, a prostaglandin derivative having one or more halogen on the ⁇ chain represented by formula (A) is obtained by reacting an aldehyde (1) and a 2-oxoalkylphosphonate (2) in the presence of an alkali hydroxide as sole base and wherein no zinc compound is used in the reaction system.
- a prostaglandin derivative represented by formula (B): may be prepared using an aldehyde represented by formula (3) : wherein A 1 , A 2 , B, R 1 , Q, X 1 , X 2 and Z have the same meanings as described above.
- a prostaglandin derivative of formula (C) may be prepared using an aldehyde of formula (4): wherein A 1 , B, R 3 , X 1 , X 2 and Z have the same meanings as described above.
- the target product, prostaglandin derivative can be obtained in high yield by simple procedures. There is no need to use a heavy metal reagent like zinc compound. On the other hand, for instance when a base such as alkaline metal hydride is used alone, prostaglandin derivative having a halogen atom on the w chain, in particular, cannot be obtained effectively.
- alkali hydroxide may be any of those shown by the formula: M-OH or M(OH) 2 ; wherein M is an alkaline metal or an alkaline earth metal.
- lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, strontium hydroxide, barium hydroxide, and the like can be cited, and preferably lithium hydroxide may be used.
- the amount of alkali hydroxide used is preferably on the order of 0.9 to 1 equivalent with respect to 2-oxoalkyl phosphonate represented by formula (2).
- the amount of 2-oxoalkyl phosphonate (2) used in the reaction is preferably on the order of 1 to 3 equivalents with respect to the aldehyde represented by formula (1), and especially, on the order of 1.1 to 2 equivalents.
- the reaction solvent is not limited in particular, and for instance, ethers, such as, ethyl ether, dimethoxy ethane, t -butyl methyl ether, diisopropyl ether, tetrahydrofuran and dioxane, aromatic compounds, such as, benzene and toluene, and halogenated hydrocarbons such as dichloroethane are preferred, and ethers are particularly preferred.
- ethers such as, ethyl ether, dimethoxy ethane, t -butyl methyl ether, diisopropyl ether, tetrahydrofuran and dioxane
- aromatic compounds such as, benzene and toluene
- halogenated hydrocarbons such as dichloroethane
- the amount of reaction solvent used in the reaction may be 1 to 100ml with respect to 1g of aldehyde (1), and especially, 10 to 50ml.
- the reaction temperature may be 0 to 100°C, and especially, 20 to 80°C.
- the reaction time may be 1 to 100 hours, especially 10 to 50 hours when at least one of X 1 and X 2 is a halogen, in particular a fluorine, and especially, 1 to 5 hours extent when X 1 and X 2 are other than halogen.
- the reaction system may comprise water.
- the amount of water added to the reaction may be 0.5 to 10% with respect to the reaction solvent, and especially, of 1 to 4%.
- reaction mixture was added to water and extracted twice with t -butyl methyl ether.
- organic layers were combined, sequentially washed with water, saturated sodium bicarbonate water and saturated aqueous sodium chloride, and then dried with anhydrous magnesium sulfate.
- reaction mixture was added to water and washed twice with t -butyl methyl ether.
- organic layers were combined, sequentially washed with saturated sodium bicarbonate water and saturated aqueous sodium chloride, and then dried with anhydrous magnesium sulfate.
- the reaction mixture was concentrated under reduced pressure, ethyl acetate (366ml) and water (280ml) were added to the residue and the mixture was stirred, let to stand and then separated into two layers.
- the aqueous layer was extracted twice with ethyl acetate (224ml).
- the organic layers were combined and washed with 1N-hydrochloric acid (336ml), saturated sodium bicarbonate water (336ml) and saturated aqueous sodium chloride (336ml). After drying with anhydrous magnesium sulfate (51g), the solution was concentrated under reduced pressure.
- the aqueous layer was extracted twice with dichloromethane (302ml). The organic layers were combined and sequentially washed with 0.35N-hydrochloric acid (302ml), water (605ml), saturated sodium bicarbonate water (605ml) and saturated aqueous sodium chloride (605ml). After drying with anhydrous magnesium sulfate (52g), the solution was concentrated under reduced pressure. The residue was dissolved in a suitable amount of ethyl acetate/hexane solvent mix (1:10), and insoluble matter was filtered.
- the aldehyde (2) used in the present invention was prepared by the following method.
- the reaction mixture was cooled on ice, diazabicycloundecene (39.0ml, 261mmol) and methyl iodide (16.3ml, 261mmol) were added, then, the mixture was stirred at room temperature for 1.25 hours.
- the reaction mixture was again cooled on ice, and diazabicycloundecene (39.0ml, 261mmol) and methyl iodide (16.3ml, 261mmol) were added.
- the reaction mixture was concentrated under reduced pressure. Ethyl acetate (400ml) and water (400ml) were added to the residue and the mixture was stirred, let to stand and then separated into two layers.
- the aqueous layer was extracted twice with ethyl acetate (400ml), the organic layers were combined and sequentially washed with 1N-hydrochloric acid (600ml), saturated sodium bicarbonate water (800ml) and saturated aqueous sodium chloride (800ml). After drying with anhydrous magnesium sulfate, the solution was concentrated under reduced pressure.
- Triethylamine (113ml, 811mmol) was added drop wise to the reaction and the reaction mixture was warmed to 0°C.
- Water (426ml) was added to the reaction mixture and the mixture was stirred, let to stand and then separated into two layers.
- the aqueous layer was extracted twice with t -butyl methyl ether (266ml).
- the organic layers were combined and sequentially washed with 1N-hydrochloric acid (390ml), water (426ml), saturated sodium bicarbonate water (426ml) and saturated aqueous sodium chloride (426ml). After drying with anhydrous magnesium sulfate (54g), the solution was concentrated under reduced pressure.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (8)
- Verfahren zur Herstellung eines Prostaglandinderivats der Formel (A):wobei A1 ein Wasserstoff oder eine Schutzgruppe für eine Hydroxygruppe ist;Y -OA2 ist, wobei A2 ein Wasserstoff oder eine Schutzgruppe einer Hydroxygruppe ist;W -R1-Q ist, wobei R1 ein gesättigter oder ungesättigter zweiwertiger niederer oder mittlerer aliphatischer Kohlenwasserstoffrest ist, welcher unsubstituiert oder substituiert ist mit Halogen, Niederalkyl, Hydroxy, Oxo, Aryl oder Heterocyclyl, und wenigstens eines der Kohlenstoffatome in dem aliphatischen Kohlenwasserstoff gegebenenfalls durch Sauerstoff, Stickstoff oder Schwefel substituiert ist, Q -CH3, -COCH3, -OH, -COOH oder ein funktionelles Derivat davon ist; oderwobei R1' ein zweiwertiger gesättigter oder ungesättigter niederer bis mittlerer aliphatischer Kohlenwasserstoffrest ist;R3 ein gesättigter oder ungesättigter niederer bis mittlerer aliphatischer Kohlenwasserstoffrest ist, welcher unsubstituiert oder mit einer niederen Alkoxy-, einer niederen Alkanoyloxy-, einer Cyclo(nieder)alkyl-, einer Cyclo(nieder)alkyloxy-, einer Aryl-, einer Aryloxy-, einer Heterocyclyl- oder einer Heterocyclyloxy-; einer Cyclo(nieder)alkylgruppe; einer Cyclo(nieder)alkyloxygruppe; einer Arylgruppe; einer Aryloxygruppe; einer Heterocyclylgruppe; einer Heterocyclyloxygruppe substituiert ist;X1 und X2 ein Wasserstoff, eine Niederalkylgruppe oder ein Halogen sind; undZ =CH- oder -CH=CH- ist,
mit der Maßgabe, dass -OA1 und Q gemeinsam
welches umfasst: Umsetzen eines durch die Formel (1)wobei Y, W und A1 dieselben Bedeutungen wie oben besitzen;B eine Einfachbindung oder -CH2- ist,
mit einem 2-Oxoalkylphosphonat, dargestellt durch die Formel (2) :wobei X1, X2 und R3 dieselben Bedeutungen wie oben besitzen; undR2 eine Niederalkylgruppe ist;in einem Reaktionslösungsmittel in Gegenwart von Alkalihydroxid als einziger Base, und wobei keine Zinkverbindung verwendet wird. - Verfahren gemäß Anspruch 1, wobei wenigstens eines aus X1 und X2 ein Halogen ist.
- Verfahren gemäß Anspruch 1, wobei sowohl X1 als auch X2 Halogen sind.
- Verfahren gemäß Anspruch 1, wobei sowohl X1 als auch X2 Fluor sind.
- Verfahren gemäß Anspruch 1, wobei das Reaktionslösungsmittel etwa 0,5 bis 10% Wasser umfasst.
- Verfahren gemäß Anspruch 1, wobei das Reaktionslösungsmittel ein Ether ist.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14156136.5A EP2735566A1 (de) | 2006-02-07 | 2007-02-06 | Verfahren zur Herstellung von Prostaglandin-Derivaten |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76572806P | 2006-02-07 | 2006-02-07 | |
PCT/JP2007/052432 WO2007091697A2 (en) | 2006-02-07 | 2007-02-06 | Method for preparing prostaglandin derivative |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14156136.5A Division EP2735566A1 (de) | 2006-02-07 | 2007-02-06 | Verfahren zur Herstellung von Prostaglandin-Derivaten |
EP14156136.5A Division-Into EP2735566A1 (de) | 2006-02-07 | 2007-02-06 | Verfahren zur Herstellung von Prostaglandin-Derivaten |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1981867A2 EP1981867A2 (de) | 2008-10-22 |
EP1981867B1 true EP1981867B1 (de) | 2017-06-14 |
Family
ID=38294011
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14156136.5A Withdrawn EP2735566A1 (de) | 2006-02-07 | 2007-02-06 | Verfahren zur Herstellung von Prostaglandin-Derivaten |
EP07714040.8A Not-in-force EP1981867B1 (de) | 2006-02-07 | 2007-02-06 | Verfahren zur herstellung eines prostaglandinderivats |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP14156136.5A Withdrawn EP2735566A1 (de) | 2006-02-07 | 2007-02-06 | Verfahren zur Herstellung von Prostaglandin-Derivaten |
Country Status (8)
Country | Link |
---|---|
US (4) | US7812182B2 (de) |
EP (2) | EP2735566A1 (de) |
JP (2) | JP4851467B2 (de) |
KR (2) | KR101353187B1 (de) |
CN (4) | CN103804338A (de) |
CA (4) | CA2856659C (de) |
HU (1) | HUE034571T2 (de) |
WO (1) | WO2007091697A2 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101318948B (zh) * | 2008-04-01 | 2011-04-27 | 上海天伟生物制药有限公司 | 鲁比前列酮晶体、其制备方法及用途 |
US8513441B2 (en) * | 2008-08-29 | 2013-08-20 | Alphora Research Inc. | Prostaglandin synthesis and intermediates for use therein |
WO2010083597A1 (en) * | 2009-01-22 | 2010-07-29 | Apotex Pharmachem Inc. | Methods of making lubiprostone and intermediates thereof |
WO2013005817A1 (en) * | 2011-07-01 | 2013-01-10 | R-Tech Ueno, Ltd. | Method for preparing a fatty acid derivative |
CN103058907B (zh) * | 2011-10-21 | 2016-05-11 | 武汉启瑞药业有限公司 | 鲁比前列酮或其中间体的制备方法 |
CN103787942B (zh) * | 2012-11-02 | 2017-02-15 | 上海源力生物技术有限公司 | 一种制备鲁比前列酮的中间体、其制备方法以及通过其制备鲁比前列酮的方法 |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
CN104140410B (zh) * | 2013-05-09 | 2017-12-15 | 江苏豪森药业集团有限公司 | 鲁比前列酮的制备方法 |
KR20160015100A (ko) | 2014-07-30 | 2016-02-12 | 미래파인켐 주식회사 | 프로스타글란딘 중간체의 제조방법 |
KR20170025682A (ko) | 2015-08-31 | 2017-03-08 | 미래파인켐 주식회사 | 프로스타글란딘 유도체의 신규한 제조방법 |
US10457623B1 (en) | 2018-07-13 | 2019-10-29 | Chirogate International Inc. | Process for the preparation of Lubiprostone and intermediates thereof |
US10253011B1 (en) * | 2018-07-13 | 2019-04-09 | Chirogate International Inc. | Lubiprostone crystals and methods for preparing the same |
EP3950672A4 (de) | 2019-03-27 | 2023-01-11 | Kyowa Pharma Chemical Co., Ltd. | Verfahren zur herstellung von prostaglandin |
CN114341098B (zh) * | 2019-10-11 | 2024-03-12 | 国立大学法人东北大学 | 环戊烷化合物的制备方法、内酯化合物的制备方法、二醇化合物的制备方法和化合物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1494321A (en) * | 1974-08-08 | 1977-12-07 | Ici Ltd | Prostanoic acid derivatives |
DE2963017D1 (en) * | 1978-10-24 | 1982-07-22 | Ici Plc | Prostane derivatives, processes for their preparation and their pharmaceutical compositions |
DE3106149A1 (de) * | 1981-02-13 | 1982-09-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | (13e)-(8r,11r,12r,15s,16rs)-11,15-dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadiensaeure sowie deren salze, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen |
US5166174A (en) * | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
TW197439B (de) * | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
DE69327717T2 (de) * | 1992-09-30 | 2000-06-21 | R-Tech Ueno, Ltd. | Verfahren zur herstellung von alpha, beta-ungesättigten ketonen |
CZ287482B6 (cs) * | 1994-01-13 | 2000-12-13 | Spolana Neratovice, A.S. | Způsob výroby alkyl 7-(substituovaných cyklopentyl)-heptanoátů |
CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
TW367324B (en) * | 1995-08-16 | 1999-08-21 | Ono Pharmaceutical Co | Prostaglandin derivatives |
US5741810A (en) | 1996-02-29 | 1998-04-21 | Allergan | Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents |
DK0857718T3 (da) * | 1996-06-10 | 2002-12-16 | Sucampo Ag | Endothelinantagonist |
DE69714274T3 (de) * | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
JP3480549B2 (ja) * | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
CN1206997C (zh) * | 1997-11-28 | 2005-06-22 | 株式会社·R-技术上野 | 内皮缩血管肽拮抗剂 |
DK1220849T3 (da) * | 1999-10-15 | 2004-09-27 | Sucampo Ag | Sammensætninger med bicykliske forbindelser og fremgangsmåde til stabilisering heraf |
EP1168174A1 (de) * | 2000-06-19 | 2002-01-02 | Hewlett-Packard Company, A Delaware Corporation | Verfahren zur automatischen Datensicherung und -wiederherstellung |
US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
JP4597481B2 (ja) * | 2001-05-18 | 2010-12-15 | スキャンポ・アーゲー | 下剤組成物 |
GB0112699D0 (en) * | 2001-05-24 | 2001-07-18 | Resolution Chemicals Ltd | Process for the preparation of prostglandins and analogues thereof |
IL159632A0 (en) * | 2001-07-17 | 2004-06-01 | Upjohn Co | Process and intermediates to prepare latanoprost |
RS81604A (en) * | 2002-03-28 | 2006-12-15 | Applied Research Systems Ars Holding N.V. | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor |
US7321057B2 (en) * | 2004-08-02 | 2008-01-22 | R-Tech Ueno, Ltd. | Method for manufacturing prostaglandin analogue |
JP4648340B2 (ja) * | 2006-02-07 | 2011-03-09 | 株式会社アールテック・ウエノ | 15−ケトプロスタグランジンe誘導体の製造法 |
-
2007
- 2007-02-06 KR KR1020087021771A patent/KR101353187B1/ko active IP Right Grant
- 2007-02-06 EP EP14156136.5A patent/EP2735566A1/de not_active Withdrawn
- 2007-02-06 EP EP07714040.8A patent/EP1981867B1/de not_active Not-in-force
- 2007-02-06 CA CA2856659A patent/CA2856659C/en active Active
- 2007-02-06 JP JP2007542938A patent/JP4851467B2/ja active Active
- 2007-02-06 CN CN201410053608.0A patent/CN103804338A/zh active Pending
- 2007-02-06 CA CA2856675A patent/CA2856675C/en active Active
- 2007-02-06 CA CA2637797A patent/CA2637797C/en active Active
- 2007-02-06 CN CN201110235768.3A patent/CN102391237B/zh active Active
- 2007-02-06 KR KR1020137019708A patent/KR101437302B1/ko active IP Right Grant
- 2007-02-06 WO PCT/JP2007/052432 patent/WO2007091697A2/en active Application Filing
- 2007-02-06 CA CA2819844A patent/CA2819844C/en active Active
- 2007-02-06 HU HUE07714040A patent/HUE034571T2/en unknown
- 2007-02-06 CN CN201410053537.4A patent/CN103755737A/zh active Pending
- 2007-02-06 CN CN200780004932.1A patent/CN101379051B/zh active Active
- 2007-02-07 US US11/703,138 patent/US7812182B2/en active Active
-
2010
- 2010-04-19 US US12/762,906 patent/US8304562B2/en active Active
- 2010-04-19 US US12/762,917 patent/US8389748B2/en active Active
- 2010-04-19 US US12/762,890 patent/US8236969B2/en active Active
-
2011
- 2011-09-01 JP JP2011190900A patent/JP5421332B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1981867B1 (de) | Verfahren zur herstellung eines prostaglandinderivats | |
US4338332A (en) | Fluoro-prostaglandins | |
JP3207203B2 (ja) | α,β−不飽和ケトンの製造法 | |
EP2726472B1 (de) | Verfahren zur herstellung eines fettsäurederivats | |
JPS5888354A (ja) | 11−デオキシ−11−アルキル−6−オキソ−pge | |
US4425359A (en) | Fluoro-prostaglandins and process for their preparation | |
SE431090B (sv) | Optiskt aktiv eller racemisk fluor-prostaglandinforening till anvendning som luteolytiskt och abortivt medel | |
Theil et al. | Prostaglandins and Prostaglandin Intermediates. XVII [1]. Synthesis of the Main Metabolite of the PGF2α Analogue Cloprostenol | |
US4414407A (en) | Fluoro-prostaglandins and process for their preparation | |
JPH072676B2 (ja) | ビシクロ〔4.3.0〕ノネン誘導体 | |
DK155317B (da) | 13,14-dehydro-prostaglandin-f2alfa-derivater til anvendelse i midler med abortfremkaldende aktivitet |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080814 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HIRATA, RYU Inventor name: MATSUKAWA, TATSUYA Inventor name: MASUZAKI, KAZUHIRO Inventor name: UENO, RYUJI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: UENO, RYUJI Inventor name: HIRATA, RYU Inventor name: MATSUKAWA, TATSUYA Inventor name: MASUZAKI, KAZUHIRO |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SUCAMPO AG Owner name: R-TECH UENO, LTD. |
|
17Q | First examination report despatched |
Effective date: 20130821 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20161215 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: R-TECH UENO, LTD. Owner name: SUCAMPO AG |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 900826 Country of ref document: AT Kind code of ref document: T Effective date: 20170615 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602007051303 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOHEST AG, CH Ref country code: CH Ref legal event code: PUEA Owner name: SUCAMPO AG, JP Free format text: FORMER OWNER: R-TECH UENO, LTD., CH |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602007051303 Country of ref document: DE Owner name: SUCAMPO AG, CH Free format text: FORMER OWNERS: SUCAMPO AG, ZUG, CH; R-TECH UENO, LTD., TOKYO, JP Ref country code: DE Ref legal event code: R081 Ref document number: 602007051303 Country of ref document: DE Owner name: SUCAMPO PHARMA, LLC, JP Free format text: FORMER OWNERS: SUCAMPO AG, ZUG, CH; R-TECH UENO, LTD., TOKYO, JP |
|
RAP2 | Party data changed (patent owner data changed or rights of a patent transferred) |
Owner name: SUCAMPO PHARMA, LLC Owner name: SUCAMPO AG |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170614 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170915 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20171019 AND 20171025 Ref country code: AT Ref legal event code: MK05 Ref document number: 900826 Country of ref document: AT Kind code of ref document: T Effective date: 20170614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170914 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20171014 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E034571 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602007051303 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20180131 Year of fee payment: 12 Ref country code: GB Payment date: 20180222 Year of fee payment: 12 |
|
26N | No opposition filed |
Effective date: 20180315 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20180118 Year of fee payment: 12 Ref country code: IT Payment date: 20180228 Year of fee payment: 12 Ref country code: HU Payment date: 20180103 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20180228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180228 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180228 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180228 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602007051303 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190206 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190207 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190206 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190903 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190206 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190228 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170614 |